Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

NCT06047535 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: Naxitamab

Sponsor

SciClone Pharmaceuticals